Viveve Medical (VIVE) 10-Q 14 May 20 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 13, 2020
Document Information [Line Items]
Entity Registrant Name	VIVEVE MEDICAL, INC.
Entity Central Index Key	0000879682
Trading Symbol	vive
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		15,091,577
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Stock

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019	[1]
Current assets:
Cash and cash equivalents	$ 9,042,000	$ 13,308,000
Accounts receivable, net of allowance for doubtful accounts of $481 and $407 as of March 31, 2020 and December 31, 2019, respectively	1,279,000	1,573,000
Inventory	4,459,000	4,861,000
Prepaid expenses and other current assets	2,204,000	2,447,000
Total current assets	16,984,000	22,189,000
Property and equipment, net	2,973,000	3,046,000
Investment in limited liability company	1,034,000	1,216,000
Other assets	441,000	526,000
Total assets	21,432,000	26,977,000
Current liabilities:
Accounts payable	2,262,000	1,608,000
Accrued liabilities	2,323,000	4,698,000
Total current liabilities	4,585,000	6,306,000
Note payable, noncurrent portion	4,110,000	3,983,000
Other noncurrent liabilities	186,000	167,000
Total liabilities	8,881,000	10,456,000
Commitments and contingences (Note 8)
Stockholders’ equity:
Common stock, $0.0001 par value; 75,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 10,028,203 and 7,075,684 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively	1,000	1,000
Additional paid-in capital	216,771,000	214,431,000
Accumulated deficit	(204,221,000)	(197,911,000)
Total stockholders’ equity	12,551,000	16,521,000
Total liabilities and stockholders’ equity	21,432,000	26,977,000
Series A Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock
Series B Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	[1]
Accounts receivable, allowance for doubtful accounts	$ 481	$ 407
Convertible preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	10,028,203	7,075,684
Common stock, shares outstanding (in shares)	10,028,203	7,075,684
Series A Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares issued (in shares)	0	1,852,173
Convertible preferred stock, shares outstanding (in shares)	0	1,852,173
Series B Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares issued (in shares)	32,667	31,678
Convertible preferred stock, shares outstanding (in shares)	32,667	31,678
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue	$ 1,304,000	$ 3,012,000
Cost of revenue	1,129,000	1,941,000
Gross profit	175,000	1,071,000
Operating expenses:
Research and development	1,637,000	2,480,000
Selling, general and administrative	4,365,000	6,626,000
Restructuring costs		742,000
Total operating expenses	6,002,000	9,848,000
Loss from operations	(5,827,000)	(8,777,000)
Interest expense, net	(210,000)	(1,116,000)
Other expense, net	(91,000)	(11,000)
Net loss from consolidated companies	(6,128,000)	(9,904,000)
Loss from minority interest in limited liability company	(182,000)	(125,000)
Comprehensive and net loss	(6,310,000)	(10,029,000)
Series B convertible preferred stock dividends	(989,000)
Net loss attributable to common stockholders	$ (7,299,000)	$ (10,029,000)
Net loss per share of common stock:
Basic and diluted (in dollars per share)	$ (0.82)	$ (21.63)
Weighted average shares used in computing net loss per common share:
Basic and diluted (in shares)	8,930,744	463,719

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	November 2019 Offering [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	November 2019 Offering [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	November 2019 Offering [Member]Common Stock [Member]	November 2019 Offering [Member]Additional Paid-in Capital [Member]	November 2019 Offering [Member]Retained Earnings [Member]	November 2019 Offering [Member]	Series A Warrants [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Series A Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Series A Warrants [Member]Common Stock [Member]	Series A Warrants [Member]Additional Paid-in Capital [Member]	Series A Warrants [Member]Retained Earnings [Member]	Series A Warrants [Member]	Series B Warrants [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Series B Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Series B Warrants [Member]Common Stock [Member]	Series B Warrants [Member]Additional Paid-in Capital [Member]	Series B Warrants [Member]Retained Earnings [Member]	Series B Warrants [Member]	Preferred Stock [Member]Series A Preferred Stock [Member]	Preferred Stock [Member]Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Series B Preferred Stock [Member]	Total
Balances (in shares) at Dec. 31, 2018																					463,630
Balances at Dec. 31, 2018																						$ 160,297	$ (155,385)		$ 4,912
Stock-based compensation expense																						470			470
Issuance of common shares from employee stock purchase plan (in shares)																					429
Issuance of common shares from employee stock purchase plan																						35			35
Issuance of restricted shares (in shares)																					6
Issuance of restricted shares																						1			1
Net loss																							(10,029)		(10,029)
Issuance of restricted common shares in connection with consulting agreement (in shares)																					274
Issuance of restricted common shares in connection with consulting agreement																						25			25
Balances (in shares) at Mar. 31, 2019																					464,339
Balances at Mar. 31, 2019																						160,828	(165,414)		(4,586)
Balances (in shares) at Dec. 31, 2018																					463,630
Balances at Dec. 31, 2018																						160,297	(155,385)		4,912
Series B convertible preferred stock dividends (in shares)																								378
Balances (in shares) at Dec. 31, 2019																			1,852,173	31,678	7,075,684
Balances at Dec. 31, 2019																					$ 1	214,431	(197,911)		16,521	[1]
Issuance costs in connection with November 2019 Offering				$ (30)		$ (30)
Conversion of Series A convertible preferred stock into common stock (in shares)																			(1,852,173)
Conversion of Series A convertible preferred stock into common stock
Conversion of Series A convertible preferred stock into common stock (in shares)																					1,852,173
Issuance of common shares in connection with warrant exercises (in shares)									1,026,240						45,473
Issuance of common shares in connection with warrant exercises										$ 1,591		$ 1,591				$ 70		$ 70
Series B convertible preferred stock dividends (in shares)																				989				989
Series B convertible preferred stock dividends																						(1)			(1)
Stock-based compensation expense																						686			686
Issuance of common shares from employee stock purchase plan (in shares)																					320
Issuance of common shares from employee stock purchase plan
Issuance of restricted shares (in shares)																					28,313
Issuance of restricted shares																						24			24
Net loss																							(6,310)		(6,310)
Balances (in shares) at Mar. 31, 2020																				32,667	10,028,203
Balances at Mar. 31, 2020																					$ 1	$ 216,771	$ (204,221)		$ 12,551
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020		Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (6,310,000)		$ (10,029,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for doubtful accounts	74,000		111,000
Depreciation and amortization	323,000		311,000
Stock-based compensation	710,000		496,000
Non-cash interest expense	127,000		399,000
Amortization of operating lease right-of-use assets and accretion of operating lease liabilities	5,000		10,000
Loss from minority interest in limited liability company	182,000		125,000
Changes in assets and liabilities:
Accounts receivable	220,000		815,000
Inventory	313,000		206,000
Prepaid expenses and other current assets	243,000		(559,000)
Other noncurrent assets	417,000		17,000
Accounts payable	654,000		(1,310,000)
Accrued and other liabilities	(2,654,000)		(2,202,000)
Other noncurrent liabilities	(40,000)		52,000
Net cash used in operating activities	(5,736,000)		(11,558,000)
Cash flows from investing activities:
Purchase of property and equipment	(161,000)		(179,000)
Net cash used in investing activities	(161,000)		(179,000)
Cash flows from financing activities:
Transaction costs in connection with November 2019 Offering	(30,000)
Proceeds from exercise of Series A and B common warrants	1,661,000
Proceeds from issuance of common shares from employee stock purchase plan			35,000
Net cash provided by financing activities	1,631,000		35,000
Net decrease in cash and cash equivalents	(4,266,000)		(11,702,000)
Cash and cash equivalents - beginning of period	13,308,000	[1]	29,523,000
Cash and cash equivalents - end of period	9,042,000		17,821,000
Supplemental disclosure:
Cash paid for interest			675,000
Cash paid for income taxes
Supplemental disclosure of cash flow information as of end of period:
Issuance of Series B convertible preferred stock in settlement of dividends	989,000
Issuance of note payable in settlement of accrued interest	126,000		318,000
Net transfer of equipment between inventory and property and equipment	89,000		46,000
Operating cash outflows from operating leases	75,000		73,000
Right-of-use assets obtained in exchange for operating lease liabilities (upon adoption of ASC 842)			$ 629,000
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) designs, develops, manufactures and markets a platform medical technology, which we refer to as Cryogen-cooled Monopolar RadioFrequency 2019 In November 2019, “November 2019 $11,500,000, $9,922,000. The offering comprised of: ( 1 $1.55 one one $1.55 first one $1.55 fifth 2 $1.55 one one one $1.55 first one $1.55 fifth The securities comprising the units were immediately separable and were issued separately. A total of 1,945,943 5,473,410 7,419,353 7,419,353 In November December 2019, 600,000 3,021,237 January February 2020, 1,183,151 669,022 March 31, 2020, no In February 2020, 1,026,240 $1,591,000. February 2020, 45,473 $70,000. March 31, 2020, 6,393,113 7,373,800 In connection with the closing of the November 2019 $28,981,000 $31,300,000, 31,300 9,893,776 6 5 120% $1.53 $1.836 one ATM Equity Offerings The Company established an “at-the-market” equity offering program through the filing of a prospectus supplement to its shelf registration statement on Form S- 3, August 16, 2019, may $6,760,000 “August 2019 $6,760,000 August 2019 September 2019. December 31, 2019, 1,004,171 August 2019 $6,322,000. three March 31, 2020 2019, zero November 2017 March 31, 2020, no August 2019 Interim Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Viveve Medical have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10 8 03 X. not The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Annual Report on Form 10 December 31, 2019, March 19, 2020. three March 31, 2020 not December 31, 2020 Liquidity and Management Plans The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standard Codification (“ASC”) Topic 205 40, one The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. However, since inception, the Company has sustained significant operating losses and such losses are expected to continue for the foreseeable future. As of March 31, 2020, $204,221,000, $9,042,000 $12,399,000. $5,736,000 three March 31, 2020. May 2021. not one To fund further operations, the Company will need to raise additional capital. The Company may no not no no

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Reverse Stock Split The Company effected a 1 100 September 18, 2019. not No $6,000. The par value of the Company’s common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75,000,000. The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company’s equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100 Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three March 31, 2020, one 48% three March 31, 2019, three 42% There were no 10% three March 31, 2020 2019. As of March 31, 2020, two 49% December 31, 2019, two 49% Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $481,000 March 31, 2020 $407,000 December 31, 2019. There were no three March 31, 2020 2019. Revenue from Contracts with Cus t omers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company’s operating leases for the Viveve System generally have a rental period of six nine June 30, 2019 not March 31, 2020 December 31, 2019, $703,000 $662,000, three March 31, 2020, $297,000 December 31, 2019. In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No March 31, 2020 December 31, 2019. $25,000 $108,000, not March 31, 2020 December 31, 2019, three March 31, 2020, $83,000 December 31, 2019. The following table reflects the changes in our customer contract liabilities for the three March 31, 2020: March 31, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ 25 $ 108 $ (83 ) Total $ 25 $ 108 $ (83 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one three March 31, 2020 2019, not Contract Costs The Company expects that commissions paid to obtain subscriptions are recoverable and has therefore capitalized them as a contract costs in the amount of $211,000 $337,000 March 31, 2020 December 31, 2019, June 30, 2019 no three March 31, 2019. three March 31, 2020 2019, $198,000 no one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three March 31, 2020 2019 Three Months Ended March 31, 2020 2019 North America $ 688 $ 1,792 Asia Pacific 597 967 Europe and Middle East 5 246 Latin America 14 - Other - 7 Total $ 1,304 $ 3,012 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three March 31, 2020 2019. Product Warranty The Company’s products sold to customers are generally subject to warranties between one three not Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three March 31, 2020 2019, Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive: Three Months Ended March 31, 2020 2019 Series B convertible preferred stock 32,667 (a) - Warrants to purchase common stock 23,665,905 6,408 Stock options to purchase common stock 10,432,654 55,864 Restricted common stock awards 2,620 4,176 (a) Each share of Series B preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1 653.59 $1,000 $1.53 not Recently Issued and Adopted Accounting Standards In November 2019, 2019 08, 718 606 718. December 15, 2019, January 1, 2020 not In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021 not not no We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no March 31, 2020 December 31, 2019. The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of March 31, 2020, December 31, 2019 There were no

Note 4 - Investment in Limited

Note 4 - Investment in Limited Liability Company	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	4. Investment in Limited Liability Company On August 8, 2017, Under the terms of the Distributorship Agreement, ICM agreed to not third not three March 31, 2020 2019, 120 300 $10,000 $27,000, March 31, 2020, 4,920 $10,000 $27,000 three March 31, 2020 2019, no March 31, 2020 December 31, 2019. In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 not March 31, 2020, 7% three three March 31, 2020 2019, $182,000 $125,000, In February 2019, no

Note 5 - Accrued Liabilities

Note 5 - Accrued Liabilities	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	5. Accrued Liabilities Accrued liabilities consisted of the following as of March 31, 2020 December 31, 2019 ( March 31, December 31, 2020 2019 Accrued payroll and other related expenses $ 719 $ 839 Deferred revenue - subscription rental program 703 662 Current operating lease liabilities 278 268 Accrued professional fees 224 592 Accrued bonuses 215 726 Accrued sales commission 60 281 Accrued inventory - 474 Accrued interest - 440 Other accruals 124 416 Total accrued liabilities $ 2,323 $ 4,698

Note 6 - Note Payable

Note 6 - Note Payable	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Note Payable On May 22, 2017, December 12, 2017 November 29,2018 “2017 $20,000,000 $10,000,000 $30,000,000 December 29, 2017, $10,000,000 A portion of the initial loan proceeds were used to repay all of the amounts owed by the Company under its 2016 2017 may In connection with the 2017 two 10 2,220 $950.00 10 Under the 2017 November 12, 2019 six four 2017 12.5%, 4.0% may, three March 31, 2019, $318,000 5.0% As security for its obligations under the 2017 The terms of the 2017 $2,000,000 2022, not 2.0 2017 On November 12, 2019, 2017 No. 3” $28,981,000 $31,300,000. 31,300 9,893,776 5 120% $1.53 $1.836 9 one The Amendment No. 3 2017 ● repayment provisions were amended such that repayment is permitted only with, or after, the redemption in full of the Series B convertible preferred stock issued to CRG; ● the interest only payment period and the period during which the Company may 23rd first no 2017 ● modified certain of the covenants, including (i) to permit issuance of the Series B convertible preferred stock and any preferred stock issued in the equity financing and the exercise and performance by the Company of its rights and obligations in connection with such CRG preferred stock and any preferred stock issued in the equity financing, (ii) eliminate the Company’s ability to enter into permitted acquisitions, (iii) further restrict the incurrence of additional indebtedness and removal of the equity cure right, and (iv) eliminate the minimum revenue requirement; and ● the back-end facility fee on the aggregate remaining principal balance on the term loan shall be increased from 5% 25%. During the three March 31, 2020, $126,000 As of March 31, 2020, As of March 31, 2020 December 31, 2019, $4,110,000 $3,983,000, The Company accounted for the changes in the 2017 31,300 9,893,776 November 26, 2019 1 $0.869 November 26, 2019); ( 2 73%; 3 2 4 1.58%. $1,023.23 $32,027,000. $3,502,000 10 $6,705,000, December 31, 2019. As of March 31, 2020, Year Ending December 31, 2020 (remaining 9 months) $ - 2021 - 2022 - 2023 5,992 Total payments 5,992 Less: Amount representing interest (1,871 ) Present value of obligations 4,121 Less: Unamortized debt discount (11 ) Note payable, noncurrent portion $ 4,110

Note 7 - Leases

Note 7 - Leases	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	7. Leases Lessee: The following information pertains to those operating lease agreements where the Company is the lessee. On February 1, 2017, 12,400 January 26, 2017. June 1, 2017 May 2021. June 2017. The monthly base rent under the Sublease is equal to $20.50 first $21.12 $21.75 second third $22,000. $88,000 In September 2018, 36 September 20, 2018. $3,000. After the adoption of ASU 842 January 1, 2019, 12 not The following table reflects the Company's lease assets and lease liabilities at March 31, 2020 December 31, 2019 ( March 31, December 31, 2020 2019 Assets: Operating lease right-of-use assets $ 332 $ 395 Liabilities: Current operating lease liabilities $ 278 $ 268 Noncurrent operating lease liabilities 59 132 $ 337 $ 400 The operating lease right-of-use assets are included in other assets on the condensed consolidated balance sheet. The operating lease liabilities are included in accrued liabilities and other noncurrent liabilities on the condensed consolidated balance sheet. The operating leases expense for the three March 31, 2020 2019 $76,000 $75,000, As of March 31, 2020, Year Ending December 31, 2020 (remaining 9 months) $ 228 2021 137 Total lease payments 365 Less: Amount representing interest (28 ) Present value of lease liabilities $ 337 The weighted average remaining lease term was approximately 14 March 31, 2020. three March 31, 2020 12.5%. Lessor: The following information pertains to those operating lease agreements where the Company is the lessor. As of March 31, 2020 , Year Ending December 31, 2020 (remaining 9 months) $ 660 2021 43 Thereafter - Total $ 703 As of March 31, 2020, $1,163,000 three March 31, 2020 $113,000.

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may not

Note 9 - Preferred Stock

Note 9 - Preferred Stock	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Preferred Stock [Text Block]	9. Preferred Stock In connection with the closing of the public offering in November 2019, With certain exceptions, as described in the Series A Certificate of Designation, the shares of Series A preferred stock have no Each share of Series A convertible preferred stock is convertible at any time at the holder’s option into one In November December 2019, 600,000 3,021,237 January February 2020, 1,183,151 669,022 March 31, 2020, no As previously reported (see Note 6 31,300 9,893,776 November 26, 2019, 12.5% December 31, 2019, 378 $2,400 three March 31, 2020, 989 $1,000 March 31, 2020, 32,667 no The Series B convertible preferred stock provides that for so long as any shares are outstanding, the consent of the holders of the Series B convertible preferred stockholders would be required to amend the Company’s organizational documents, approve any merger, sale of assets, or other major corporate transaction, or incur additional indebtedness, among other items. The fair value of the Series B convertible preferred stock was determined in connection with the CRG debt conversion as part of the accounting for that transaction as a troubled debt restructuring. (See Note 6 November 26, 2019, $1,023.23 $32,027,000 31,300 Under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not

Note 10 - Common Stock

Note 10 - Common Stock	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. Common Stock In November 2019, “November 2019 $11,500,000, $9,922,000. The offering comprised of: ( 1 $1.55 one one $1.55 first one $1.55 fifth 2 $1.55 one one one $1.55 first one $1.55 fifth The securities comprising the units were immediately separable and were issued separately. A total of 1,945,943 5,473,410 7,419,353 7,419,353 In November December 2019, 600,000 3,021,237 January February 2020, 1,183,151 669,022 In February 2020, 1,026,240 $1,591,000. In February 2020, 45,473 $70,000. ATM Equity Offerings Through the August 2019 may $6,760,000 $6,760,000 August 2019 September 2019. three September 30, 2019, 1,004,171 August 2019 $6,322,000. Restricted Common Shares In March 2020, 28,313 $24,000. In December 2019, 30,675 $25,000. In October 2019, 7,740 $25,000. In March 2019, 274 $25,000. Warrants for Common Stock As of March 31, 2020, Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 400.00 754 March 2015 Common Shares March 26, 2025 $ 272.00 14 May 2015 Common Shares May 12, 2025 $ 424.00 362 May 2015 Common Shares May 17, 2020 $ 424.00 215 December 2015 Common Shares December 16, 2025 $ 560.00 267 April 2016 Common Shares April 1, 2026 $ 608.00 250 May 2016 Common Shares May 11, 2021 $ 774.00 50 June 2016 Common Shares June 20, 2026 $ 498.00 1,004 May 2017 Common Shares May 25, 2027 $ 950.00 2,220 November 2019 Common Shares November 26, 2020 $ 1.55 6,393,113 November 2019 Common Shares November 26, 2024 $ 1.55 7,373,880 November 2019 Common Shares November 26, 2024 $ 1.84 9,893,776 23,665,905 In connection with the November 2019 7,419,353 7,419,353 one $1.55 first one $1.55 fifth one one $1.55 one five $1.55 $1,210,000 0%, 91.1%, 1.59% one $2,871,000 0%, 68.8%, 1.58% five $4,081,000 November 2019 In February 2020, 1,026,240 $1,591,000. February 2020, 45,473 $70,000. March 31, 2020, 6,393,113 7,373,800 In connection with the CRG Debt Conversion, CRG received warrants exercisable for 9,893,776 15% November 2019 five 120% $1.53 $1.836 $3,502,000 0%, 68.8%, 1.58% five In connection with the 2017 2,220, $950.00 ten $940,000 0%, 55.1%, 2.25% ten $790,000, three March 31, 2020 2019, $1,000 $83,000, March 31, 2020, $11,000. No three March 31, 2020 2019. No three March 31, 2020 2019. The stock-based compensation expense related to warrants issued was zero three March 31, 2020 2019, no

Note 11 - Summary of Stock Opti

Note 11 - Summary of Stock Options	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	1 1 . Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards (“RSAs”) from two 2006 “2006 2013 “2013 As of March 31, 2020, 2006 104 no $992.00 2.8 As of March 31, 2020, 2013 10,432,550 4,093,287 $1.94 9.7 In January 2020, 2020 2013 2,639,926 11,872,531 14,512,457 January 1, 2020. Activity under the 2006 2013 Three Months Ended March 31, 2020 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 10,087,678 $ 2.22 9.9 $ 3,928,715 Options granted 468,000 $ 0.88 Options exercised - Options canceled (123,024 ) $ 20.25 Options outstanding, end of period 10,432,654 $ 1.95 9.7 $ - Vested and exercisable and expected to vest, end of period 9,404,561 $ 2.04 9.7 $ - Vested and exercisable, end of period 833,785 $ 9.63 9.6 $ - The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s closing share price as of March 31, 2020. The options outstanding and exercisable as of March 31, 2020 Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices March 31, 2020 Price Term (Years) March 31, 2020 Price $0.69 - $0.89 10,238,979 $ 0.86 9.7 813,153 $ 0.87 $1.09 - $1.36 155,000 $ 1.26 9.9 - $ - $38.00 - $58.00 1,600 $ 55.81 9.2 - $ - $100.00 - $197.00 20,352 $ 141.85 8.6 9,174 $ 147.74 $202.00 - $283.00 743 $ 251.21 7.6 392 $ 254.90 $311.00 - $382.00 2,625 $ 344.68 8.4 1,238 $ 345.28 $430.00 - $497.00 6,707 $ 454.33 7.3 4,281 $ 455.78 $501.00 - $567.00 3,215 $ 537.49 7.1 2,432 $ 536.76 $600.00 - $661.00 1,392 $ 602.19 5.8 1,375 $ 601.46 $700.00 - $792.00 1,937 $ 767.72 6.6 1,636 $ 767.47 $992.00 - $992.00 104 $ 992.00 2.8 104 $ 992.00 Total: 10,432,654 $ 1.95 9.7 833,785 $ 9.63 Restricted Stock Awards During the three March 31, 2020, no 2013 In July 2019, 378 2013 $38.08 378 In June 2019, 250 June 2018. In April 2019, 525 2013 $91.00 525 In January 2019, 3,625 2013 2018 2018 50% 50% three March 31, 2020, zero March 31, 2020, zero As of March 31, 2020, 2,620 2017 The tenth 2017 “2017 January 1, 2020 March 31, 2020, 320 March 31, 2020 $0.59. The ninth 2017 October 1, 2019 December 31, 2019, 300 December 31, 2019 $1.07. The eighth 2017 July 1, 2019 September 30, 2019, 200 September 30, 2019 $3.75. The seventh 2017 April 1, 2019 June 30, 2019, 602 June 28, 2019 $32.30. The sixth 2017 January 1, 2019 March 31, 2019, 429 March 29, 2019 $79.88. As of March 31, 2020, 2017 772 The Company estimates the fair value of purchase rights under the ESPP using a Black-Scholes valuation model. The fair value of each purchase right was estimated on the date of grant using the Black-Scholes option valuation model and the straight-line attribution approach with the following weighted-average assumptions: Three Months Ended March 31, 2020 2019 Expected term (in years) 0.25 0.25 Average volatility 124% 74% Risk-free interest rate 1.54% 2.45% Dividend yield 0% 0% The weighted average grant date fair value of the purchase rights issued under the 2017 three March 31, 2020 2019 $0.43 $33.00, Stock-Based Compensation During the three March 31, 2020 2019, 368,000 21,175 $0.75 $123.66 no three March 31, 2020 2019. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Three Months Ended March 31, 2020 2019 Expected term (in years) 5 5 Average volatility 73% 73% Risk-free interest rate 0.45% 2.53% Dividend yield 0% 0% During the three March 31, 2020 2019, 100,000 275 $1.36 $121.82 no three March 31, 2020 2019. The fair value of nonemployee stock options granted was estimated using the following weighted average assumptions: Three Months Ended March 31, 2020 2019 Expected term (in years) 5 5 Average volatility 73% 73% Risk-free interest rate 1.39% 2.49% Dividend yield 0% 0% Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and the Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No not not The following table shows stock-based compensation expense included in the condensed consolidated statements of operations for the three March 31, 2020 2019 Three Months Ended March 31, 2020 2019 Cost of revenue $ 60 $ 32 Research and development 87 40 Selling, general and administrative 564 424 Total 710 $ 496 As of March 31, 2020, $7,341,000. 3.1

Note 12 - Income Taxes

Note 12 - Income Taxes	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	1 2 . Income Taxes No no For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. The Company’s effective tax rate is 0% three March 31, 2020. 2020 0%. The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020

Note 13 - Related Party Transac

Note 13 - Related Party Transactions	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	1 3 . Related Party Transactions In June 2006, October 4, 2007. 300 March 31, 2020, 855 375 $282,000 $1,489,000 three March 31, 2020 2019, March 31, 2020 December 31, 2019 $323,000 $124,000, In August 2017, February 2019, no

Note 14 - Restructuring Costs

Note 14 - Restructuring Costs	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	1 4 . Restructuring Costs In January 2019, 40 $742,000 first 2019

Note 15 - Subsequent Events

Note 15 - Subsequent Events	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	1 5 . Subsequent Events On April 24, 2020, $1,343,400 1.00% two seven may No On April 15, 2020, $1.55 $0.61 April 16, 2020, 4,820,584 242,790 $3.1 2 4,820,584 2 242,790 $0.6371 five April 20, 2020.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Reserve Stock Split, Policy [Policy Text Block]	Reverse Stock Split The Company effected a 1 100 September 18, 2019. not No $6,000. The par value of the Company’s common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75,000,000. The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company’s equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three March 31, 2020, one 48% three March 31, 2019, three 42% There were no 10% three March 31, 2020 2019. As of March 31, 2020, two 49% December 31, 2019, two 49%
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $481,000 March 31, 2020 $407,000 December 31, 2019. There were no three March 31, 2020 2019.
Revenue from Contract with Customer [Policy Text Block]	Revenue from Contracts with Cus t omers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company’s operating leases for the Viveve System generally have a rental period of six nine June 30, 2019 not March 31, 2020 December 31, 2019, $703,000 $662,000, three March 31, 2020, $297,000 December 31, 2019. In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No March 31, 2020 December 31, 2019. $25,000 $108,000, not March 31, 2020 December 31, 2019, three March 31, 2020, $83,000 December 31, 2019. The following table reflects the changes in our customer contract liabilities for the three March 31, 2020: March 31, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ 25 $ 108 $ (83 ) Total $ 25 $ 108 $ (83 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one three March 31, 2020 2019, not Contract Costs The Company expects that commissions paid to obtain subscriptions are recoverable and has therefore capitalized them as a contract costs in the amount of $211,000 $337,000 March 31, 2020 December 31, 2019, June 30, 2019 no three March 31, 2019. three March 31, 2020 2019, $198,000 no one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three March 31, 2020 2019 Three Months Ended March 31, 2020 2019 North America $ 688 $ 1,792 Asia Pacific 597 967 Europe and Middle East 5 246 Latin America 14 - Other - 7 Total $ 1,304 $ 3,012 The Company determines geographic location of its revenue based upon the destination of the shipments of its products.
Equity Method Investments [Policy Text Block]	Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three March 31, 2020 2019.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company’s products sold to customers are generally subject to warranties between one three not
Share-based Payment Arrangement [Policy Text Block]	Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three March 31, 2020 2019,
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive: Three Months Ended March 31, 2020 2019 Series B convertible preferred stock 32,667 (a) - Warrants to purchase common stock 23,665,905 6,408 Stock options to purchase common stock 10,432,654 55,864 Restricted common stock awards 2,620 4,176 (a) Each share of Series B preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1 653.59 $1,000 $1.53 not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued and Adopted Accounting Standards In November 2019, 2019 08, 718 606 718. December 15, 2019, January 1, 2020 not In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021 not not no We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	March 31, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ 25 $ 108 $ (83 ) Total $ 25 $ 108 $ (83 )
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended March 31, 2020 2019 North America $ 688 $ 1,792 Asia Pacific 597 967 Europe and Middle East 5 246 Latin America 14 - Other - 7 Total $ 1,304 $ 3,012
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2020 2019 Series B convertible preferred stock 32,667 (a) - Warrants to purchase common stock 23,665,905 6,408 Stock options to purchase common stock 10,432,654 55,864 Restricted common stock awards 2,620 4,176

Note 5 - Accrued Liabilities (T

Note 5 - Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, December 31, 2020 2019 Accrued payroll and other related expenses $ 719 $ 839 Deferred revenue - subscription rental program 703 662 Current operating lease liabilities 278 268 Accrued professional fees 224 592 Accrued bonuses 215 726 Accrued sales commission 60 281 Accrued inventory - 474 Accrued interest - 440 Other accruals 124 416 Total accrued liabilities $ 2,323 $ 4,698

Note 6 - Note Payable (Tables)

Note 6 - Note Payable (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2020 (remaining 9 months) $ - 2021 - 2022 - 2023 5,992 Total payments 5,992 Less: Amount representing interest (1,871 ) Present value of obligations 4,121 Less: Unamortized debt discount (11 ) Note payable, noncurrent portion $ 4,110

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Lessee, Lease Assets and Liabilities [Table Text Block]	March 31, December 31, 2020 2019 Assets: Operating lease right-of-use assets $ 332 $ 395 Liabilities: Current operating lease liabilities $ 278 $ 268 Noncurrent operating lease liabilities 59 132 $ 337 $ 400
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending December 31, 2020 (remaining 9 months) $ 228 2021 137 Total lease payments 365 Less: Amount representing interest (28 ) Present value of lease liabilities $ 337
Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]	Year Ending December 31, 2020 (remaining 9 months) $ 660 2021 43 Thereafter - Total $ 703

Note 10 - Common Stock (Tables)

Note 10 - Common Stock (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 400.00 754 March 2015 Common Shares March 26, 2025 $ 272.00 14 May 2015 Common Shares May 12, 2025 $ 424.00 362 May 2015 Common Shares May 17, 2020 $ 424.00 215 December 2015 Common Shares December 16, 2025 $ 560.00 267 April 2016 Common Shares April 1, 2026 $ 608.00 250 May 2016 Common Shares May 11, 2021 $ 774.00 50 June 2016 Common Shares June 20, 2026 $ 498.00 1,004 May 2017 Common Shares May 25, 2027 $ 950.00 2,220 November 2019 Common Shares November 26, 2020 $ 1.55 6,393,113 November 2019 Common Shares November 26, 2024 $ 1.55 7,373,880 November 2019 Common Shares November 26, 2024 $ 1.84 9,893,776 23,665,905

Note 11 - Summary of Stock Op_2

Note 11 - Summary of Stock Options (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Three Months Ended March 31, 2020 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 10,087,678 $ 2.22 9.9 $ 3,928,715 Options granted 468,000 $ 0.88 Options exercised - Options canceled (123,024 ) $ 20.25 Options outstanding, end of period 10,432,654 $ 1.95 9.7 $ - Vested and exercisable and expected to vest, end of period 9,404,561 $ 2.04 9.7 $ - Vested and exercisable, end of period 833,785 $ 9.63 9.6 $ -
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices March 31, 2020 Price Term (Years) March 31, 2020 Price $0.69 - $0.89 10,238,979 $ 0.86 9.7 813,153 $ 0.87 $1.09 - $1.36 155,000 $ 1.26 9.9 - $ - $38.00 - $58.00 1,600 $ 55.81 9.2 - $ - $100.00 - $197.00 20,352 $ 141.85 8.6 9,174 $ 147.74 $202.00 - $283.00 743 $ 251.21 7.6 392 $ 254.90 $311.00 - $382.00 2,625 $ 344.68 8.4 1,238 $ 345.28 $430.00 - $497.00 6,707 $ 454.33 7.3 4,281 $ 455.78 $501.00 - $567.00 3,215 $ 537.49 7.1 2,432 $ 536.76 $600.00 - $661.00 1,392 $ 602.19 5.8 1,375 $ 601.46 $700.00 - $792.00 1,937 $ 767.72 6.6 1,636 $ 767.47 $992.00 - $992.00 104 $ 992.00 2.8 104 $ 992.00 Total: 10,432,654 $ 1.95 9.7 833,785 $ 9.63
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended March 31, 2020 2019 Expected term (in years) 5 5 Average volatility 73% 73% Risk-free interest rate 0.45% 2.53% Dividend yield 0% 0% Three Months Ended March 31, 2020 2019 Expected term (in years) 5 5 Average volatility 73% 73% Risk-free interest rate 1.39% 2.49% Dividend yield 0% 0%
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2020 2019 Cost of revenue $ 60 $ 32 Research and development 87 40 Selling, general and administrative 564 424 Total 710 $ 496
2017 Employee Stock Purchase Plan [Member]
Notes Tables
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	Three Months Ended March 31, 2020 2019 Expected term (in years) 0.25 0.25 Average volatility 124% 74% Risk-free interest rate 1.54% 2.45% Dividend yield 0% 0%

Note 1 - The Company and Basi_2

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)	Nov. 26, 2019	Nov. 12, 2019	Aug. 16, 2019	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019		Nov. 30, 2019	Aug. 31, 2019	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Nov. 30, 2019	Dec. 31, 2019		Dec. 31, 2018
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)										23,665,905
Proceeds from Warrant Exercises										$ 1,661,000
Retained Earnings (Accumulated Deficit), Ending Balance						$ (197,911,000)	[1]			(204,221,000)				$ (197,911,000)	[1]
Cash and Cash Equivalents, at Carrying Value, Ending Balance						$ 13,308,000	[1]			9,042,000		17,821,000		$ 13,308,000	[1]	$ 29,523,000
Working Capital										12,399,000
Net Cash Provided by (Used in) Operating Activities, Total										$ (5,736,000)		$ (11,558,000)
Conversion of Term Loan with CRG Into Stock and Warrants [Member]
Debt Conversion, Original Debt, Amount		$ 28,981,000
Debt Conversion, Converted Instrument, Amount		$ 31,300,000
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	31,300	31,300
Series A Convertible Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)				669,022	1,183,151	3,021,237		600,000
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member]
Conversion of Stock, Conversion Rate (in dollars per share)		$ 1.53
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member]
Conversion of Stock, Conversion Rate (in dollars per share)		$ 1.836
Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)								1		1			1
Preferred Stock, Shares Outstanding, Ending Balance (in shares)						1,852,173	[2]			0				1,852,173	[2]
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)										0
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)								1					1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 1.55		$ 1.55			$ 1.55
Warrants and Rights Outstanding, Term (Year)								1 year					1 year
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								7,419,353		6,393,113			7,419,353
Stock Issued During Period, Shares, Warrant Exercises (in shares)				1,026,240
Proceeds from Warrant Exercises				$ 1,591,000
Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)								1					1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 1.55		$ 1.55			$ 1.55
Warrants and Rights Outstanding, Term (Year)								5 years					5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								7,419,353		7,373,880			7,419,353
Stock Issued During Period, Shares, Warrant Exercises (in shares)				45,473
Proceeds from Warrant Exercises				$ 70,000
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)										$ 1.84
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	9,893,776	9,893,776								9,893,776
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate		120.00%
Class A Units [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)								1					1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 1.55					$ 1.55
Warrants and Rights Outstanding, Term (Year)								1 year					1 year
Class A Units [Member] | Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)								1					1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 1.55					$ 1.55
Warrants and Rights Outstanding, Term (Year)								5 years					5 years
Class B Units [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)								1					1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 1.55					$ 1.55
Warrants and Rights Outstanding, Term (Year)								1 year					1 year
Class B Units [Member] | Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)								1					1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 1.55					$ 1.55
Warrants and Rights Outstanding, Term (Year)								5 years					5 years
Common Stock [Member] | Series A Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)										1,026,240
Common Stock [Member] | Series B Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)										45,473
November 2019 Offering [Member]
Proceeds from Issuance or Sale of Equity, Total								$ 11,500,000
Proceeds From Issuance of Common Stock, Net								$ 9,922,000
November 2019 Offering [Member] | Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)								5,473,410
November 2019 Offering [Member] | Class A Units [Member]
Shares Issued, Price Per Share (in dollars per share)								$ 1.55					$ 1.55
Common Shares Per Unit (in shares)								1					1
November 2019 Offering [Member] | Class B Units [Member]
Shares Issued, Price Per Share (in dollars per share)								$ 1.55					$ 1.55
Series A Convertible Preferred Stock Per Unit (in shares)								1					1
November 2019 Offering [Member] | Class B Units [Member] | Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)								1					1
November 2019 Offering [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)								1,945,943					1,945,943
August 2019 ATM Facility [Member]
Proceeds From Issuance of Common Stock, Net											$ 6,322,000			$ 6,322,000
Stock Issued During Period, Shares, New Issues (in shares)											1,004,171			1,004,171
Aggregate Offering Price			$ 6,760,000						$ 6,760,000
Stock Issued During Period, Shares, New Issues (in shares)										0
November 2017 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues (in shares)										0		0
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.
[2]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Sep. 18, 2019USD ($)	Mar. 31, 2020USD ($)$ / sharesshares	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)$ / sharesshares		Nov. 30, 2019shares
Payments for Fractional Shares of Reverse Stock Split	$ 6,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares		$ 0.0001		$ 0.0001	[1]
Common Stock, Shares Authorized (in shares) | shares		75,000,000		75,000,000	[1]
Number of Financial Institutions		1
Accounts Receivable, Allowance for Credit Loss, Ending Balance		$ 481,000		$ 407,000
Accounts Receivable, Allowance for Credit Loss, Writeoff		0	$ 0
Deferred Income		703,000		662,000
Contract with Customer, Liability, Revenue Recognized		297,000
Contract with Customer, Asset, after Allowance for Credit Loss, Total		0		0
Contract with Customer, Liability, Total		25,000		108,000
Capitalized Contract Cost, Net, Total		211,000		337,000
Capitalized Contract Cost, Impairment Loss		0	0
Capitalized Contract Cost, Amortization		198,000	0
Equity Method Investment, Other than Temporary Impairment		$ 0	$ 0
Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | shares		1				1
Series B Preferred Stock [Member]
Conversion of Stock Exchange Ratio		653.59
Preferred Stock, Liquidation Preference Per Share (in dollars per share) | $ / shares		$ 1,000
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares		$ 1.53
Minimum [Member]
Warranty Period (Year)		1 year
Maximum [Member]
Warranty Period (Year)		3 years
Marketing Programs [Member]
Contract with Customer, Liability, Revenue Recognized		$ 83,000
Contract with Customer, Liability, Total		$ 25,000		$ 108,000
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Number of Customers		1	3
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]
Concentration Risk, Percentage		48.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Three Customers [Member]
Concentration Risk, Percentage			42.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Number of Customers		2		2
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage		49.00%		49.00%
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	100
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Customer Contract Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Customer contract liabilities	$ 25,000	$ 108,000
Change in customer contract liabilities	(83,000)
Marketing Programs [Member]
Customer contract liabilities	25,000	$ 108,000
Change in customer contract liabilities	$ (83,000)

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue	$ 1,304	$ 3,012
North America [Member]
Revenue	688	1,792
Asia Pacific [Member]
Revenue	597	967
Europe And Middle East [Member]
Revenue	5	246
Latin America [Member]
Revenue	14
Other [Member]
Revenue		$ 7

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2020		Mar. 31, 2019
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	32,667	[1]
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	23,665,905		6,408
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	10,432,654		55,864
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	2,620		4,176
[1]	Each share of Series B preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1-for-653.59 per share determined by dividing the Series B liquidation amount of $1,000 per share by the Series B conversion price of $1.53 per share. However, under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not convert the Series B preferred stock or exercise the CRG warrants until the Company’s stockholders act to authorize additional number of shares of common stock sufficient to cover the conversion shares.

Note 4 - Investment in Limite_2

Note 4 - Investment in Limited Liability Company (Details Textual)	Aug. 08, 2017USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Income (Loss) from Equity Method Investments, Total		$ (182,000)	$ (125,000)
InControl Medical [Member]
Equity Method Investment, Ownership Percentage		7.00%		7.00%
Income (Loss) from Equity Method Investments, Total		$ 182,000	$ 125,000
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Unrecorded Unconditional Purchase Obligation, Period Quantity Purchased		120	300	4,920
Unrecorded Unconditional Purchase Obligation, Purchases		$ 10,000	$ 27,000
Payments for Purchase of Products		10,000	$ 27,000
Accounts Payable, Related Parties, Current		$ 0		$ 0	$ 0
Payments to Acquire Equity Method Investments	$ 2,500,000

Note 5 - Accrued Liabilities -

Note 5 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accrued payroll and other related expenses	$ 719	$ 839
Deferred revenue - subscription rental program	703	662
Accrued professional fees	224	592
Accrued bonuses	215	726
Accrued sales commission	60	281
Accrued inventory		474
Accrued interest		440
Other accruals	124	416
Total accrued liabilities	2,323	4,698	[1]
Accrued Liabilities [Member]
Current operating lease liabilities	$ 278	$ 268
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Note 6 - Note Payable (Details

Note 6 - Note Payable (Details Textual)	Nov. 26, 2019USD ($)$ / sharesshares	Nov. 12, 2019USD ($)$ / sharesshares	Dec. 29, 2017USD ($)	May 22, 2017USD ($)$ / sharesshares	Mar. 31, 2020USD ($)$ / sharesshares	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares					23,665,905
Notes Payable, Noncurrent, Total					$ 4,110,000		$ 3,983,000	[1]
Share Price (in dollars per share) | $ / shares	$ 0.869
Gains (Losses) on Restructuring of Debt	$ (6,705,000)
Series B Preferred Stock [Member]
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares					$ 1.53
Preferred Stock, Fair Value, Per Share (in dollars per share) | $ / shares	$ 1,023.23
Convertible Preferred Stock, Fair Value	$ 32,027,000
Series B Preferred Stock [Member] | Measurement Input, Option Volatility [Member]
Convertible Preferred Stock, Measurement Input	73
Series B Preferred Stock [Member] | Measurement Input, Expected Term [Member]
Convertible Preferred Stock, Measurement Input	2
Series B Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Convertible Preferred Stock, Measurement Input	1.58
Minimum [Member] | Series B Convertible Preferred Stock Into Common Stock [Member]
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares		$ 1.53
Maximum [Member] | Series B Convertible Preferred Stock Into Common Stock [Member]
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares		$ 1.836
Conversion of Term Loan with CRG Into Stock and Warrants [Member]
Debt Conversion, Original Debt, Amount		$ 28,981,000
Debt Conversion, Converted Instrument, Amount		$ 31,300,000
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares	31,300	31,300
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Warrants and Rights Outstanding, Term (Year)				10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares				2,220	2,220
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 950	$ 950
Warrants and Rights Outstanding				$ 940,000
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	9,893,776	9,893,776			9,893,776
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 1.84
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate		120.00%
Warrants and Rights Outstanding	$ 3,502,000	$ 3,502,000
The 2017 Loan Agreement [Member] | CRG LP [Member]
Debt Instrument, Face Amount				20,000,000
Debt Agreement, Covenant, Additional Funding				10,000,000
Debt Agreement, Maximum Borrowing Capacity				$ 30,000,000
Proceeds from Lines of Credit, Total			$ 10,000,000
Debt Instrument, Term (Year)				6 years
Debt instrument, Interest Only Payment, Period (Year)				4 years
Debt Instrument, Interest Rate, Stated Percentage				12.50%
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period				4.00%
Paid-in-Kind Interest					$ 126,000	$ 318,000
Debt Instrument, Prepayment Fee, Percentage				5.00%
Debt Instrument, Covenant, Cash and Cash Equivalents				$ 2,000,000
Debt Instrument, Back-end Facility Fee Percentage of Principal		25.00%		5.00%
Notes Payable, Noncurrent, Total					$ 4,110,000		$ 3,983,000
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Note 6 - Note Payable - Summary

Note 6 - Note Payable - Summary of Note Payable (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019	[1]
2020 (remaining 9 months)
2021
2022
2023	5,992,000
Total payments	5,992,000
Less: Amount representing interest	(1,871,000)
Present value of obligations	4,121,000
Less: Unamortized debt discount	(11,000)
Note payable, noncurrent portion	$ 4,110,000	$ 3,983,000
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual)	1 Months Ended	3 Months Ended
	Sep. 30, 2018USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)		Feb. 01, 2017USD ($)ft²
Operating Leases, Rent Expense, Total		$ 76,000	$ 75,000
Operating Lease, Weighted Average Remaining Lease Term (Month)		1 year 60 days
Operating Lease, Weighted Average Discount Rate, Percent				12.50%
Operating Lease, Property Plant and Equipment, Amount		$ 2,973,000		$ 3,046,000	[1]
Lessor, Operating Lease, Depreciation on Leased Assets		323,000	$ 311,000
Assets Leased to Others [Member]
Operating Lease, Property Plant and Equipment, Amount		1,163,000
Lessor, Operating Lease, Depreciation on Leased Assets		$ 113,000
Sublease Agreement for Relocation of Headquarters [Member]
Area of Real Estate Property (Square Foot) | ft²						12,400
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year						20.5
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year						21.12
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year						21.75
Security Deposit						$ 22,000
Operating Leases, Allowance for Certain Improvements						$ 88,000
Noncancelable Operating Lease Agreement for Office Equipment [Member]
Lessee, Operating Lease, Term of Contract (Month)	3 years
Operating Leases, Monthly Payment	$ 3,000
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Note 7 - Leases - Lease Assets

Note 7 - Leases - Lease Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Operating lease right-of-use assets	$ 332	$ 395
Accrued Liabilities [Member]
Current operating lease liabilities	278	268
Other Noncurrent Liabilities [Member]
Noncurrent operating lease liabilities	59	132
Accrued Liabilities and Other Noncurrent Liabilities [Member]
Operating Lease, Liability, Total	$ 337	$ 400

Note 7 - Leases - Maturity of O

Note 7 - Leases - Maturity of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
2020 (remaining 9 months)	$ 228
2021	137
Total lease payments	365
Less: Amount representing interest	(28)
Accrued Liabilities and Other Noncurrent Liabilities [Member]
Present value of lease liabilities	$ 337	$ 400

Note 7 - Leases - Minimum Futur

Note 7 - Leases - Minimum Future Rentals (Details) $ in Thousands	Mar. 31, 2020USD ($)
2020 (remaining 9 months)	$ 660
2021	43
Thereafter
Total	$ 703

Note 9 - Preferred Stock (Detai

Note 9 - Preferred Stock (Details Textual) - USD ($)	Nov. 26, 2019	Nov. 12, 2019	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019		Nov. 30, 2019	Mar. 31, 2020	Dec. 31, 2019
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								23,665,905
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	9,893,776	9,893,776						9,893,776
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	31,300	31,300
Series A Convertible Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)			669,022	1,183,151	3,021,237		600,000
Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)							1	1
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					1,852,173	[1]		0	1,852,173	[1]
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								0
Series B Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					31,678	[1]		32,667	31,678	[1]
Preferred Stock, Dividend Rate, Percentage	12.50%
Preferred Stock Dividends, Shares (in shares)								989	378
Dividends, Preferred Stock, Cash								$ 1,000	$ 2,400
Preferred Stock, Fair Value, Per Share (in dollars per share)	$ 1,023.23
Convertible Preferred Stock, Fair Value	$ 32,027,000
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)	31,300
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Note 10 - Common Stock (Details

Note 10 - Common Stock (Details Textual)	Aug. 16, 2019USD ($)	Mar. 31, 2020USD ($)$ / sharesshares	Feb. 29, 2020USD ($)shares	Jan. 31, 2020shares	Dec. 31, 2019USD ($)shares	Nov. 30, 2019USD ($)$ / sharesshares	Oct. 31, 2019USD ($)	Aug. 31, 2019USD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)shares	Mar. 31, 2019USD ($)shares	Nov. 30, 2019USD ($)$ / sharesshares	Dec. 31, 2019USD ($)shares	Nov. 26, 2019USD ($)shares	Nov. 12, 2019USD ($)$ / sharesshares	May 22, 2017USD ($)yr$ / sharesshares
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		23,665,905								23,665,905
Proceeds from Warrant Exercises | $										$ 1,661,000
Stock Issued During Period, Value, Restricted Stock Award, Gross | $												25,000
Amortization of Debt Discount (Premium) | $										1,000		$ 83,000
Debt Instrument, Unamortized Discount, Total | $		$ 11,000								$ 11,000
Class of Warrants or Rights, Exercises in Period (in shares)										0		0
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period (in shares)										0		0
Share-based Payment Arrangement, Expense | $										$ 710,000		$ 496,000
Class of Warrant or Right, Issued During Period (in shares)										0		0
The 2017 Loan Agreement [Member]
Debt Issuance Costs, Net, Total | $		790,000								$ 790,000
Restricted Stock [Member]
Proceeds From Issuance of Common Stock, Net | $		28,313			$ 30,675		$ 7,740		$ 274
Stock Issued During Period, Value, Restricted Stock Award, Gross | $		$ 24,000			$ 25,000		$ 25,000		$ 25,000
Series A Convertible Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)			669,022	1,183,151	3,021,237	600,000
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member]
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares																$ 1.53
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member]
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares																$ 1.836
Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)		1				1				1			1
Series B Preferred Stock [Member]
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares		$ 1.53								$ 1.53
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)						1							1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 1.55				$ 1.55				$ 1.55			$ 1.55
Warrants and Rights Outstanding, Term (Year)						1 year							1 year
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		6,393,113				7,419,353				6,393,113			7,419,353
Stock Issued During Period, Shares, Warrant Exercises (in shares)			1,026,240
Proceeds from Warrant Exercises | $			$ 1,591,000
Warrants and Rights Outstanding | $						$ 1,210,000							$ 1,210,000
Series A Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input						0							0
Series A Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input						91.1							91.1
Series A Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input						1.59							1.59
Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)						1							1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 1.55				$ 1.55				$ 1.55			$ 1.55
Warrants and Rights Outstanding, Term (Year)						5 years							5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		7,373,880				7,419,353				7,373,880			7,419,353
Stock Issued During Period, Shares, Warrant Exercises (in shares)			45,473
Proceeds from Warrant Exercises | $			$ 70,000
Warrants and Rights Outstanding | $						$ 2,871,000							$ 2,871,000
Series B Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input						0							0
Series B Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input						68.8							68.8
Series B Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input						1.58							1.58
Series A and Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 1.55							$ 1.55
Warrants and Rights Outstanding | $						$ 4,081,000							$ 4,081,000
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 1.84								$ 1.84
Warrants and Rights Outstanding, Term (Year)																5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		9,893,776								9,893,776					9,893,776	9,893,776
Warrants and Rights Outstanding | $															$ 3,502,000	$ 3,502,000
Class of Warrants or Rights, Outstanding, Percentage of Common Stock																15.00%
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate																120.00%
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input																0
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input																68.8
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																1.58
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 950								$ 950							$ 950
Warrants and Rights Outstanding, Term (Year)																	10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		2,220								2,220							2,220
Warrants and Rights Outstanding | $																	$ 940,000
Share-based Payment Arrangement, Expense | $										$ 0		$ 0
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input																	0
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input																	0.551
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																	0.0225
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr																	10
Class A Units [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)						1							1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 1.55							$ 1.55
Warrants and Rights Outstanding, Term (Year)						1 year							1 year
Class A Units [Member] | Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)						1							1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 1.55							$ 1.55
Warrants and Rights Outstanding, Term (Year)						5 years							5 years
Class B Units [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)						1							1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 1.55							$ 1.55
Warrants and Rights Outstanding, Term (Year)						1 year							1 year
Class B Units [Member] | Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)						1							1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 1.55							$ 1.55
Warrants and Rights Outstanding, Term (Year)						5 years							5 years
Common Stock [Member]
Stock Issued During Period, Value, Restricted Stock Award, Gross | $
Common Stock [Member] | Series A Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)										1,026,240
Common Stock [Member] | Series B Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)										45,473
November 2019 Offering [Member]
Proceeds from Issuance or Sale of Equity, Total | $						$ 11,500,000
Proceeds From Issuance of Common Stock, Net | $						$ 9,922,000
November 2019 Offering [Member] | Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)						5,473,410
November 2019 Offering [Member] | Series B Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)													5,473,410
November 2019 Offering [Member] | Class A Units [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares						$ 1.55							$ 1.55
Common Shares Per Unit (in shares)						1							1
November 2019 Offering [Member] | Class B Units [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares						$ 1.55							$ 1.55
Series A Convertible Preferred Stock Per Unit (in shares)						1							1
November 2019 Offering [Member] | Class B Units [Member] | Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)						1							1
November 2019 Offering [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)						1,945,943							1,945,943
August 2019 ATM Facility [Member]
Proceeds From Issuance of Common Stock, Net | $											$ 6,322,000			$ 6,322,000
Stock Issued During Period, Shares, New Issues (in shares)											1,004,171			1,004,171
Aggregate Offering Price | $	$ 6,760,000							$ 6,760,000

Note 10 - Common Stock - Summar

Note 10 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares	3 Months Ended
	Mar. 31, 2020	Nov. 30, 2019	Nov. 26, 2019	Nov. 12, 2019	May 22, 2017
Shares Outstanding Under Warrants (in shares)	23,665,905
Employee Performance Bonus Warrants, February 2015 Issuance [Member]
Expiration Date	Feb. 17, 2025
Exercise Price (in dollars per share)	$ 400
Shares Outstanding Under Warrants (in shares)	754
Contractor Warrants, March 2015 Issuance [Member]
Expiration Date	Mar. 26, 2025
Exercise Price (in dollars per share)	$ 272
Shares Outstanding Under Warrants (in shares)	14
Contractor Warrants, May 2015 Issuance [Member]
Expiration Date	May 12, 2025
Exercise Price (in dollars per share)	$ 424
Shares Outstanding Under Warrants (in shares)	362
May 2015 Issuance Second Contractor [Member]
Expiration Date	May 17, 2020
Exercise Price (in dollars per share)	$ 424
Shares Outstanding Under Warrants (in shares)	215
Performance Bonus Warrants, December 2015 Issuance [Member]
Expiration Date	Dec. 16, 2025
Exercise Price (in dollars per share)	$ 560
Shares Outstanding Under Warrants (in shares)	267
Distributor Warrants, April 2016 Issuance [Member]
Expiration Date	Apr. 1, 2026
Exercise Price (in dollars per share)	$ 608
Shares Outstanding Under Warrants (in shares)	250
Contractor Warrants, May 2016 Issuance [Member]
Expiration Date	May 11, 2021
Exercise Price (in dollars per share)	$ 774
Shares Outstanding Under Warrants (in shares)	50
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Expiration Date	Jun. 20, 2026
Exercise Price (in dollars per share)	$ 498
Shares Outstanding Under Warrants (in shares)	1,004
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Expiration Date	May 25, 2027
Exercise Price (in dollars per share)	$ 950				$ 950
Shares Outstanding Under Warrants (in shares)	2,220				2,220
Series A Warrants [Member]
Expiration Date	Nov. 26, 2020
Exercise Price (in dollars per share)	$ 1.55	$ 1.55
Shares Outstanding Under Warrants (in shares)	6,393,113	7,419,353
Series B Warrants [Member]
Expiration Date	Nov. 26, 2024
Exercise Price (in dollars per share)	$ 1.55	$ 1.55
Shares Outstanding Under Warrants (in shares)	7,373,880	7,419,353
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Expiration Date	Nov. 26, 2024
Exercise Price (in dollars per share)	$ 1.84
Shares Outstanding Under Warrants (in shares)	9,893,776		9,893,776	9,893,776

Note 11 - Summary of Stock Op_3

Note 11 - Summary of Stock Options (Details Textual) - USD ($)	Mar. 31, 2020	Jan. 01, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 28, 2019	Mar. 29, 2019	Jul. 31, 2019	Jun. 30, 2019	Apr. 30, 2019	Jan. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Nov. 26, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	10,432,654		10,087,678								10,432,654		10,087,678
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)	$ 1.95		$ 2.22								$ 1.95		$ 2.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)											9 years 255 days		9 years 328 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)											468,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate											0.00%	0.00%
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									525
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)							378		525
Consultant [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)								250
Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate											0.00%	0.00%
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)	2,620										2,620
Restricted Stock [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)							$ 38.08		$ 91
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate											0.00%
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 7,341,000										$ 7,341,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)											3 years 36 days
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	104										104
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	0										0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)	$ 992										$ 992
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)											2 years 292 days
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	10,432,550										10,432,550
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	4,093,287										4,093,287
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)	$ 1.94										$ 1.94
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)											9 years 255 days
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)		2,639,926
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)		14,512,457												11,872,531
The 2013 Plan [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)											368,000	21,175
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)											$ 0.75	$ 123.66
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)											0	0
The 2013 Plan [Member] | Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)											100,000	275
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)											$ 1.36	$ 121.82
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)											0	0
The 2013 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)										3,625	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)											0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)											0
2017 Employee Stock Purchase Plan [Member]
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)	320		300	200	602	429
Shares Issued, Price Per Share (in dollars per share)	$ 0.59		$ 1.07	$ 3.75	$ 32.30	$ 79.88					$ 0.59		$ 1.07
Employee Stock Ownership Plan (ESOP), Number of Suspense Shares (in shares)	772										772
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased (in dollars per share)											$ 0.43	$ 33
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate											0.00%	0.00%

Note 11 - Summary of Stock Op_4

Note 11 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Options outstanding, beginning of period (in shares)	10,087,678
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.22
Options outstanding, weighted average remaining contractual term (Year)	9 years 255 days	9 years 328 days
Options outstanding, aggregate intrinsic value		$ 3,928,715
Options granted (in shares)	468,000
Options granted, weighted average exercise price (in dollars per share)	$ 0.88
Options exercised (in shares)
Options exercised, weighted average exercise price (in dollars per share)
Options canceled (in shares)	(123,024)
Options canceled, weighted average exercise price (in dollars per share)	$ 20.25
Options outstanding, end of period (in shares)	10,432,654	10,087,678
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.95	$ 2.22
Vested and exercisable and expected to vest, end of period (in shares)	9,404,561
Vested and exercisable and expected to vest, end of period, weighted average exercise price (in dollars per share)	$ 2.04
Vested and exercisable and expected to vest, end of period, weighted average remaining contractual term (Year)	9 years 255 days
Vested and exercisable and expected to vest, end of period, aggregate intrinsic value
Vested and exercisable, end of period (in shares)	833,785
Vested and exercisable, end of period, weighted average exercise price (in dollars per share)	$ 9.63
Vested and exercisable, end of period, weighted average remaining contractual term (Year)	9 years 219 days
Vested and exercisable, end of period, aggregate intrinsic value

Note 11 - Summary of Stock Op_5

Note 11 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Options outstanding, number (in shares) | shares	10,432,654
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.95
Options outstanding, weighted average remaining contractual term (Year)	9 years 255 days
Options exercisable, number exercisable (in shares) | shares	833,785
Options exercisable, weighted average exercise price (in dollars per share)	$ 9.63
Range One [Member]
Exercise price range, lower limit (in dollars per share)	0.69
Exercise price range, upper limit (in dollars per share)	$ 0.89
Options outstanding, number (in shares) | shares	10,238,979
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.86
Options outstanding, weighted average remaining contractual term (Year)	9 years 255 days
Options exercisable, number exercisable (in shares) | shares	813,153
Options exercisable, weighted average exercise price (in dollars per share)	$ 0.87
Range Two [Member]
Exercise price range, lower limit (in dollars per share)	1.09
Exercise price range, upper limit (in dollars per share)	$ 1.36
Options outstanding, number (in shares) | shares	155,000
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.26
Options outstanding, weighted average remaining contractual term (Year)	9 years 328 days
Options exercisable, number exercisable (in shares) | shares
Options exercisable, weighted average exercise price (in dollars per share)
Range Three [Member]
Exercise price range, lower limit (in dollars per share)	38
Exercise price range, upper limit (in dollars per share)	$ 58
Options outstanding, number (in shares) | shares	1,600
Options outstanding, weighted average exercise price (in dollars per share)	$ 55.81
Options outstanding, weighted average remaining contractual term (Year)	9 years 73 days
Options exercisable, number exercisable (in shares) | shares
Options exercisable, weighted average exercise price (in dollars per share)
Range Four [Member]
Exercise price range, lower limit (in dollars per share)	100
Exercise price range, upper limit (in dollars per share)	$ 197
Options outstanding, number (in shares) | shares	20,352
Options outstanding, weighted average exercise price (in dollars per share)	$ 141.85
Options outstanding, weighted average remaining contractual term (Year)	8 years 219 days
Options exercisable, number exercisable (in shares) | shares	9,174
Options exercisable, weighted average exercise price (in dollars per share)	$ 147.74
Range Five [Member]
Exercise price range, lower limit (in dollars per share)	202
Exercise price range, upper limit (in dollars per share)	$ 283
Options outstanding, number (in shares) | shares	743
Options outstanding, weighted average exercise price (in dollars per share)	$ 251.21
Options outstanding, weighted average remaining contractual term (Year)	7 years 219 days
Options exercisable, number exercisable (in shares) | shares	392
Options exercisable, weighted average exercise price (in dollars per share)	$ 254.90
Range Six [Member]
Exercise price range, lower limit (in dollars per share)	311
Exercise price range, upper limit (in dollars per share)	$ 382
Options outstanding, number (in shares) | shares	2,625
Options outstanding, weighted average exercise price (in dollars per share)	$ 344.68
Options outstanding, weighted average remaining contractual term (Year)	8 years 146 days
Options exercisable, number exercisable (in shares) | shares	1,238
Options exercisable, weighted average exercise price (in dollars per share)	$ 345.28
Range Seven [Member]
Exercise price range, lower limit (in dollars per share)	430
Exercise price range, upper limit (in dollars per share)	$ 497
Options outstanding, number (in shares) | shares	6,707
Options outstanding, weighted average exercise price (in dollars per share)	$ 454.33
Options outstanding, weighted average remaining contractual term (Year)	7 years 109 days
Options exercisable, number exercisable (in shares) | shares	4,281
Options exercisable, weighted average exercise price (in dollars per share)	$ 455.78
Range Eight [Member]
Exercise price range, lower limit (in dollars per share)	501
Exercise price range, upper limit (in dollars per share)	$ 567
Options outstanding, number (in shares) | shares	3,215
Options outstanding, weighted average exercise price (in dollars per share)	$ 537.49
Options outstanding, weighted average remaining contractual term (Year)	7 years 36 days
Options exercisable, number exercisable (in shares) | shares	2,432
Options exercisable, weighted average exercise price (in dollars per share)	$ 536.76
Range Nine [Member]
Exercise price range, lower limit (in dollars per share)	600
Exercise price range, upper limit (in dollars per share)	$ 661
Options outstanding, number (in shares) | shares	1,392
Options outstanding, weighted average exercise price (in dollars per share)	$ 602.19
Options outstanding, weighted average remaining contractual term (Year)	5 years 292 days
Options exercisable, number exercisable (in shares) | shares	1,375
Options exercisable, weighted average exercise price (in dollars per share)	$ 601.46
Range Ten [Member]
Exercise price range, lower limit (in dollars per share)	700
Exercise price range, upper limit (in dollars per share)	$ 792
Options outstanding, number (in shares) | shares	1,937
Options outstanding, weighted average exercise price (in dollars per share)	$ 767.72
Options outstanding, weighted average remaining contractual term (Year)	6 years 219 days
Options exercisable, number exercisable (in shares) | shares	1,636
Options exercisable, weighted average exercise price (in dollars per share)	$ 767.47
Range Eleven [Member]
Exercise price range, lower limit (in dollars per share)	992
Exercise price range, upper limit (in dollars per share)	$ 992
Options outstanding, number (in shares) | shares	104
Options outstanding, weighted average exercise price (in dollars per share)	$ 992
Options outstanding, weighted average remaining contractual term (Year)	2 years 292 days
Options exercisable, number exercisable (in shares) | shares	104
Options exercisable, weighted average exercise price (in dollars per share)	$ 992

Note 11 - Summary of Stock Op_6

Note 11 - Summary of Stock Options - Valuation Assumption for Employee Stock Purchase Plan (Details)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Expected term (Year)	5 years	5 years
Average volatility	73.00%	73.00%
Risk-free interest rate	0.45%	2.53%
Dividend yield	0.00%	0.00%
2017 Employee Stock Purchase Plan [Member]
Expected term (Year)	91 days	91 days
Average volatility	124.00%	74.00%
Risk-free interest rate	1.54%	2.45%
Dividend yield	0.00%	0.00%

Note 11 - Summary of Stock Op_7

Note 11 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Expected term (Year)	5 years	5 years
Average volatility	73.00%	73.00%
Risk-free interest rate	0.45%	2.53%
Dividend yield	0.00%	0.00%
Nonemployees [Member]
Expected term (Year)	5 years	5 years
Average volatility	73.00%	73.00%
Risk-free interest rate	1.39%	2.49%
Dividend yield	0.00%	0.00%

Note 11 - Summary of Stock Op_8

Note 11 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock-based compensation expense	$ 710	$ 496
Cost of Sales [Member]
Stock-based compensation expense	60	32
Research and Development Expense [Member]
Stock-based compensation expense	87	40
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 564	$ 424

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) - USD ($) xbrli-pure in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2020
Income Tax Expense (Benefit), Total	$ 0
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%
Forecast [Member]
Effective Income Tax Rate Reconciliation, Percent, Total		0.00%

Note 13 - Related Party Trans_2

Note 13 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member] - USD ($)	3 Months Ended		123 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Stock Issued During Period, Shares, New Issues (in shares)			375
Related Party Transaction, Amounts of Transaction	$ 282,000	$ 1,489,000
Accounts Payable, Related Parties, Current	$ 323,000		$ 124,000

Note 14 - Restructuring Costs (

Note 14 - Restructuring Costs (Details Textual)	1 Months Ended	3 Months Ended
	Jan. 31, 2019USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)
Restructuring and Related Cost, Number of Positions Eliminated	40
Restructuring Charges, Total	$ 742,000		$ 742,000

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual) - USD ($)	Apr. 24, 2020	Apr. 20, 2020	Apr. 15, 2020	Mar. 31, 2020	Nov. 30, 2019
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				23,665,905
Series A and Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 1.55
Series A Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 1.55	$ 1.55
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				6,393,113	7,419,353
Warrants and Rights Outstanding, Term (Year)					1 year
Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 1.55	$ 1.55
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				7,373,880	7,419,353
Warrants and Rights Outstanding, Term (Year)					5 years
Subsequent Event [Member]
Proceeds from Paycheck Protection Program Under CARES Act	$ 1,343,400
Subsequent Event [Member] | Series A and Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.61
Proceeds from Issuance of Warrants		$ 3,100,000
Subsequent Event [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		4,820,584
Subsequent Event [Member] | Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		242,790
Subsequent Event [Member] | Series A-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		4,820,584
Subsequent Event [Member] | Series B-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		242,790
Subsequent Event [Member] | Series A-2 and Series B-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.6371
Warrants and Rights Outstanding, Term (Year)		5 years